GNTA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 4.34%, SMA50 -20.79%, SMA200 -65.34%). The stock’s 14-day RSI is 43.65 (neutral), while the ATR of 0.13 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -90.4% below its high and over 36.18% above its low. Average 10-day trading volume of 38.81 thousand shares is below the 3-month average of 98.37 thousand, indicating normal recent market interest.

Genenta Science S.p.A. generated EPS of -$0.51 over the past year. Five-year average earnings growth is -13.19%. Wall Street analysts project EPS growth of 3.62% annually over the next five years. Genenta Science S.p.A. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -36.05% in April 24, 2024.

Genenta Science S.p.A. has 18.29 million shares outstanding. The public float is 11.22 million shares, elevated short interest at 0.06% of float. This equals 6.66 thousand shares. The short ratio is 0.29 days. Institutional investors hold 17.65% of the float. Insiders own 39.15%. ROSENWALD LINDSAY A MD holds 184.87 thousand shares, Sanders Walter Lloyd has 30.63 thousand shares and Driscoll Martin J has 15.00 thousand shares.

Genenta Science S.p.A. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.12. This means the shares are trading below this model’s fair value.

Genenta Science S.p.A. (NASDAQ:GNTA) closed at $0.73 USD, gaining $0.02 (2.64%) from the previous close of $0.71. The stock is currently mid-range between its 52-week high and low $0.59 and $10.00. With a market capitalization of about $13.98 million, Genenta Science S.p.A. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.71). Key stats such as the average daily volume over the past year has been around 92.15 thousand shares, volume is running light vs its 52-week average. Headquartered in Milan, MI, Genenta Science S.p.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pierluigi Paracchi, the company employs approximately 13 people and listed since December 15, 2021. Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

Genenta Science S.p.A. trades at a P/E ratio of -2.09, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.6 suggesting the stock is closer to book value. The P/FCF stands at -6.94, also below market averages.

Our AI price prediction model suggests that Genenta Science S.p.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.57%, with price expected at $0.70 by May 14, 2026, within a range of $0.64 to $0.76 3-Month Outlook: Projected fall of -42.35%, reaching $0.41 by July 29, 2026, with a range of $0.29 to $0.52. 1-Year Outlook: Projected loss of -88.75%, with price at $0.08 by April 30, 2027, within a range of $0.00 to $0.18.

Genenta Science S.p.A. (NASDAQ:GNTA) shares are flat -9.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Genenta Science S.p.A. trading at a premium to the broader market with a P/E of -2.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.57, suggesting 2932.9% upside. Our AI forecast model points to short-term weakness (-1.57% over two weeks), a medium-term fall (-42.35% over three months), and a longer-term loss (-88.75% over one year), with expected trading ranges indicating moderate volatility.